BD Swatch pump 510(k) withdrawn; BD CY Q2 ’19 (FY Q3 ’19) Earnings Update

BD hosted their CY Q2 ’19 (FY Q3 ’19) earnings call (press release) and provided a brief update on their diabetes business unit including the 510(k) withdrawal of their Swatch pump for T2DM. Below, FENIX provides further details on the Swatch pump 510(k) withdrawal and insight into its impact on the T2DM patch pump segment.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.